AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02971345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultra-fluid lipiodol
Description: Ultra-fluid lipiodol is a kind of embolization material used in TACE. Standard: 38% ultra-fluid lipiodol .
Study NCT02971345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gelatin sponge articles
Description: Gelatin sponge articles embolization material used in TACE. Standard: 350-560 um in diameter.
Study NCT02971345 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gelatin sponge articles
Description: Gelatin sponge articles embolization material used in TACE. Standard: 350-560 um in diameter.
Study NCT03628352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tricaprilin
Description: Tricaprilin with flavoring agents added
Study NCT00439751 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Goserelin Acetate
Description: Continuous goserelin, 12 week (10.8 mg) depot, will be used as ADT for both study arms. It is supplied as a sterile syringe for subcutaneous use.
Study NCT05020054 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tecartherapy Intervention
Description: therapeutic therapy with effective application, connected equipment
Study NCT05020054 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo tecartherapy
Description: tecartherapy with equipment turned off
Study NCT01326702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride
Description: Given IV
Study NCT01326702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01326702 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT01326702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study NCT04601662 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corticision
Description: A special instrument will be used to cut the cortex of the alveolar bone at different locations between the lower anterior teeth
Study NCT04601662 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Non-accelerated Treatment
Description: The normal sequence of treatment steps will be followed in this group without using any kind of acceleration methods
Study NCT02741362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous injection of Stromal Vascular Fraction Cells (SVF) containing ADSCs
Study NCT02741362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lipoaspiration
Study NCT03533530 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Low-density ESI (LD ESI)
Description: Electrical source imaging using low density EEG
Study NCT03533530 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High-density ESI (HD ESI)
Description: Electrical source imaging using high density EEG
Study NCT03533530 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: No electrical source imaging (ESI)
Description: For all patients: MRI, semiology, visual interpretation of EEG. When needed: PET, SPECT.
Study NCT02833857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Description: A single IV-bolus dose of 0.035 mg/kg etelcalcetide into the venous line of the dialysis circuit at the end of a hemodialysis session.
Study NCT03272867 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: ProManna
Study NCT03272867 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ProManna
Study NCT00361257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Tetracycline antibiotic, 100 mg taken orally every 12 hours
Study NCT00361257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Tetracycline)
Description: Tetracycline antibiotic placebo, orally every 12 hours
Study NCT02856867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nintedanib
Study NCT02856867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Study NCT02856867 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluorouracil
Study NCT02856867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Study NCT02856867 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Leucovorin
Study NCT02856867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Study NCT02856867 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Study NCT02856867 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04079842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00029
Description: Noninvasive pulse oximeter sensor
Study NCT02626065 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: Blood samples (44mL) will be taken before starting treatment with Nivolumab and at week 2, week 12, week 54 or at relapse (before week 54)
Study NCT02626065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: injection of Nivolumab every two weeks from day 0 and until relapse, toxicity motivating withdrawal or temporary suspension of treatment or up to 54 weeks.
Study NCT04168762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial Ultrasound Magnetic Stimulation
Description: Transcranial Ultrasound Magnetic Stimulation is a paradigm that allows for concurrent and concentric ultrasound stimulation with transcranial magnetic stimulation (TMS).
Study NCT04110275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human tissue-type plasminogen activator derivative
Description: Recombinant human tissue-type plasminogen activator derivative(rPA,chemical name: Reteplase,brand name:Ruitongli) 18mg/10ml/stick, provided by AngDe Biotech Pharmaceutical Co.,LIMITED(LTD)
Study NCT04110275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human tissue-type plasminogen activator
Description: Recombinant human tissue-type plasminogen activator(rt-PA,chemical name:Alteplase,brand name: Actilyse)50mg/stick,provided by Boehringer Ingelheim Pharma Gesellschaft mit beschrankter Haftung(GmbH)\&Co,
Study NCT03689140 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoke Free Together - App-only
Description: Pregnant smokers and their life partners will use a smoking cessation app.
Study NCT03689140 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoke Free Together - Telemedicine counseling only
Description: Pregnant smokers and their life partners will use telemedicine, real time video counseling on smoking cessation
Study NCT03689140 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoke Free Together - app + telemedicine
Description: Pregnant smokers and their life partners will use telemedicine and an app for smoking cessation
Study NCT04188223 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Hepatitis B (Bio Farma) Vaccine
Description: Recombinant Hepatitis B vaccine produced by Bio Farma
Study NCT04188223 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Hepatitis B (Bio Farma) Vaccine®
Description: Registered Recombinant Hepatitis B vaccine produced by Bio Farma
Study NCT03812146 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PC-TAU
Description: PC-TAU consists of Brief Advice intervention from their PC medical provider that is built into the electronic medical record as a mandatory response to a positive screen. In addition, patients who score positive on the AUDIT-C or PC-PTSD are offered a referral to the PCMHI provider within the PC clinic. PCMHI in VA consists of licensed, independent providers (typically psychologists or clinical social workers) providing brief assessment and interventions to veterans and consultation to other members of the PC team. PCMHI sessions are typically focused on assessment, psycho-education, and supportive counseling.
Study NCT01176539 — intervention group
Intervention type: DEVICE
Intervention: Non-Contact Respiratory Rate Monitor
Description: The Non-Contact Respiratory Rate Monitor provides a measurement of respiratory rate at a single point in time for neonates, pediatrics and adults.~The Non-Contact Respiratory Rate Monitor provides a continuous monitor, measurement, and display of the respiratory rate, respiratory patterns, depth of breath, history/events and respiratory activity of a subject for neonates, pediatrics, and adults.
Study NCT01713218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Administrated intravenously at a dose of 1000 mg/m2 over 30 minutes weekly, week 1 to 4
Study NCT01713218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: 150 mg capsule, oral, once daily
Study NCT01713218 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Description: Combination of gemcitabine and Vismodegib during a window interval (4 weeks) before surgery
Study NCT00579917 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cognitive Behavioral Therapy: Questionnaires
Description: CBT, we will interview you again after you have completed the 10 sessions. We call these follow-up interviews, and they include several phone calls and a questionnaire you would be asked to complete and then mail in. Each follow-up interview will take between 60 and 210 minutes. If you wish, these follow-up interviews can be done over different days. We will do the follow-up interviews three times; at approximately 4 months, 7 months, and 10 months after you complete the baseline interview.
Study NCT00579917 — intervention group
Intervention type: BEHAVIORAL
Intervention: Usual Care: Questionnaires
Description: If you receive Usual Care, you will not receive CBT while you are in the study. You will complete the questionnaires at the same time as participants who receive CBT. If you receive Usual Care you will be offered 10 sessions of CBT at no charge at the end of the study.
Study NCT00407992 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occipital nerve stimulation ON
Description: Implant of an occipital nerve stimulator switched ON
Study NCT00407992 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Occipital nerve stimulation off
Description: Implant of an occipital nerve stimulator switched OFF
Study NCT01054820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLECTORÂ® Patch (diclofenac epolamine topical patch) 1.3%
Description: One FLECTOR Patch applied to the most painful area on the subject's back every 12 hours for up to 14 days.
Study NCT04471818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine (0.5 mg/kg) will be administered intravenously once every week to patients in the experimental arm of the study
Study NCT04471818 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (0.5 mg/kg) will be administered intravenously once every week to patients in the experimental arm of the study
Study NCT01914926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Study NCT01914926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diltiazem
Study NCT00328419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: photoprotected bags, tubing, syringes
Description: use of photoprotected parenteral nutrition device
Study NCT00328419 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard tubing and bags
Description: Use of standard (transparent) parenteral nutrition device
Study NCT03719105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Patients will receive methotrexate as part of chemoimmunotherapy regemin followed by allogeneic stem cell transplant.
Study NCT03719105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pralatraxate,
Description: Patients will receive pralaxtraxate as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
Study NCT03719105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Patients will receive Ifsofamide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
Study NCT03719105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Patients will receive dexamethasone as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
Study NCT03719105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Patients will receive etoposide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
Study NCT03719105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calaspargase pegol
Description: Patients will receive pegaspargase as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
Study NCT03719105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Patients will receive cyclophosphamide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
Study NCT03719105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Patients will receive doxorubicin as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
Study NCT03719105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Patients will receive prednisone as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
Study NCT03719105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Patients will receive brentuximab vedotin as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
Study NCT02486926 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Anesthesia of patients was maintained only with sevoflurane.
Study NCT02486926 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sevoflurane
Description: Anesthesia of patients was maintained only with sevoflurane.
Study NCT02486926 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sevoflurane
Description: Anesthesia of patients was maintained only with sevoflurane.
Study NCT02486926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Anesthesia of patients was maintained with both sevoflurane and continuous remifentanil infusion.
Study NCT02486926 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Remifentanil
Description: Anesthesia of patients was maintained with both sevoflurane and continuous remifentanil infusion.
Study NCT02486926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfentanil
Description: Anesthesia was maintained with both sevoflurane and continuous infusion of remifentanil. Alfentanil was administrated (5ug/kg) to patients 10 minutes before the end of surgery.
Study NCT02486926 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Alfentanil
Description: Anesthesia was maintained with both sevoflurane and continuous infusion of remifentanil. Alfentanil was administrated (5ug/kg) to patients 10 minutes before the end of surgery.
Study NCT02486926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiopental
Description: General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
Study NCT02486926 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Thiopental
Description: General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
Study NCT02486926 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Thiopental
Description: General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
Study NCT02486926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
Study NCT02486926 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rocuronium
Description: General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
Study NCT02486926 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rocuronium
Description: General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
Study NCT01716754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QGE031
Description: QGE031 was supplied as 120 mg liquid in vial per 1 mL
Study NCT01716754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Omalizumab was supplied as 150 mg lyophilisate in vial
Study NCT01716754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to QGE031 and Omalizumab was supplied as QGE031 0 mg in vial per 1 mL
Study NCT03877042 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cruciate-retaining (CR) prostheses
Description: One leg is conducted TKA with Cruciate-retaining (CR) prostheses.
Study NCT03877042 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posterior-stabilized (PS) prostheses
Description: One leg is conducted TKA with Posterior-stabilized (PS) prostheses.
Study NCT02605954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: 150/150/200/10 mg FDC tablets administered orally once daily
Study NCT02605954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABC/3TC
Description: 600/300 mg tablets administered orally once daily
Study NCT01988428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2000 mg
Description: Ceftriaxone 2000 mg
Study NCT02605954 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Third Antiretroviral Agent
Description: Third antiretroviral agents could include one of the following:~* ATV+cobicistat (COBI; Tybost®) or ATV/COBI FDC~* DRV+COBI or DRV/COBI FDC~* darunavir (DRV; Prezista®) + RTV~* lopinavir/ritonavir (LPV/r; Kaletra®)~* atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®)~* efavirenz (EFV; Sustiva®)~* etravirine (ETR; Intelence®)~* nevirapine (NVP; Viramune®)~* rilpivirine (RPV; Edurant®)~* dolutegravir (DTG; Tivicay®)~* raltegravir (RAL; Isentress®)~* fosamprenavir (FPV; Lexiva®) + RTV~* saquinavir (SQV; Invirase®) + RTV~* ATV (no booster)~Drug classes:~* Protease inhibitors (PI): LPV/r, ATV, RTV, ATV, DRV, FPV and SQV~* Pharmacokinetic enhancer: COBI~* Non-nucleoside reverse transcriptase inhibitors (NNRTI): EFV, RPV, NVP, and ETR~* Integrase inhibitors: RAL and DTG
Study NCT02590354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ART interruption
Study NCT02327026 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bag-valve-mask ventilation
Description: Airway management including initial bag-valve-mask ventilation by the medical team during OHCA. When standard bag-valve-mask ventilation is possible, the patient will be intubated in case of a return of spontaneous circulation. When standard bag-valve-mask ventilation is impossible or in case of massive regurgitation of gastric content (after randomisation), intubation of patient is the preferred alternative.
Study NCT02327026 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tracheal intubation
Description: Tracheal intubation during OHCA by the medical team: The standard intubation procedure is to use a non-styletted tube and no sedation. When standard laryngoscopy-assisted intubation is not possible, an alternate procedure will be used based on the French consensus conference guidelines on difficult airway management
Study NCT02513160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, taken in the morning and evening each day, was provided in matching BAI and MDI devices.~The placebo devices were identical to the devices used to deliver active drug.
Study NCT03110289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: superdonor FMT
Description: Fecal microbiota transplantation (FMT) is the transfer of feces from a healthy superdonor to the patient.
Study NCT03110289 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: autologous FMT
Description: Fecal microbiota transplantation (FMT) with feces from the patient him/herself
Study NCT01369342 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group 1: Placebo
Description: Form=solution for injection, route=intravenous use, in a single dose.
Study NCT01369342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 2 ustekinumab 130 mg
Description: Type=exact, unit=mg, number=130, form=solution for injection, route= intravenous use, in a single dose.
Study NCT01369342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 3: ustekinumab approximately 6 mg/kg
Description: Type=range, unit=mg/kg, number=6, form=solution for injection, route= intravenous use, in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight \<= 55 kg), 390 mg (weight > 55 kg and \<= 85 kg), and 520 mg (weight > 85 kg).
Study NCT00583726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interviewing
Description: telephone counseling
Study NCT03658278 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Juven
Description: Nutritional supplement (Juven) will be consumed daily per manufacturer recommendations